Biblio

Found 359 results
[ Author(Asc)] Keyword Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
K
G. B. Kristensen, Vergote, I. B., Stuart, G. C. E., Del Campo, J. M., Kaern, J., Lopez, A. B., Eisenhauer, E., Åvall-Lundqvist, E., Ridderheim, M., Havsteen, H., Mirza, M. R., Scheistroen, M., and Vrdoljak, E., First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin., Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 172-7, 2003.
G. B. Kristensen, Perren, T. J., Qian, W., Pfisterer, J., Ledermann, J. A., Joly, F., Carey, M. S., Beale, P., Cervantes, A., and Oza, A. M., Result of interim analysis of overall survival in the phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. , J Clin Oncol , vol. 29, no. suppl; abstr LBA5006, 2011.
S. Kommoss, du Bois, A., Ridder, R., Trunk, M. J., Schmidt, D., Pfisterer, J., Kommoss, F., and -OVAR, A. G. O., Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaek, Br J Cancer, vol. 96, pp. 306-13, 2007.
H. C. Kitchener, Management of endometrial cancer., Eur J Surg Oncol, vol. 32, no. 8, pp. 838-43, 2006.
H. C. Kitchener, Hoskins, W. J., Small, W., Thomas, G. M., Trimble, E. L., and Group, C. Cancer Con, The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report, Int J Gynecol Cancer, vol. 20, pp. 1092-100, 2010.
H. C. Kitchener, Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer., Cancer Treat Rev, vol. 31, no. 4, pp. 323-7, 2005.
H. C. Kitchener and Trimble, E. L., Endometrial cancer state of the science meeting., Int J Gynecol Cancer, vol. 19, no. 1, pp. 134-40, 2009.
H. M. Keys, Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D., Pearlman, A., Maiman, M. A., Bell, J. G., and Group, G. Oncology, A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, vol. 92, pp. 744-51, 2004.
S. B. Kaye, Paul, J., Cassidy, J., Lewis, C. R., Duncan, I. D., Gordon, H. K., Kitchener, H. C., Cruickshank, D. J., Atkinson, R. J., Soukop, M., Rankin, E. M., Davis, J. A., Reed, N. Simon, Crawford, S. M., MacLean, A., Parkin, D., Sarkar, T. K., Kennedy, J., Symonds, R. P., and Group, S. Gynaecolog, Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group, J Clin Oncol, vol. 14, pp. 2113-9, 1996.
S. B. Kaye and Group, S. Gynaecolog, The integration of docetaxel into first-line chemotherapy for ovarian cancer, Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 31-3, 2001.
N. Katsumata, Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., Ochiai, K., Noda, K., and Group, J. Gynecologi, Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial, Lancet, vol. 374, pp. 1331-8, 2009.
N. Katsumata, Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., Sugiyama, T., Ochiai, K., and Group, J. Gynecologi, Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial, Lancet Oncol, vol. 14, pp. 1020-6, 2013.
K. Katherine, Julia, B., Valerie, B., Oza, A. M., and Stephanie, L., Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention , Frontiers in Oncology , vol. 6, no. 00119 , 2016.
B. K, Kaern, J., Simonsen, E., Piccart, M. J., G, H. Boes, Timmers, P., Roy, J. - A., Pecorelli, S., Stuart, G. C. E., James, K., Cassidy, J., and Kaye, S. B., Is cisplatin-taxol the standard treatment in advanced ovarian cancer., Eur.J.Can. , vol. 33, no. 8, 1997.
H
P. Hoskins, Eisenhauer, E., Vergote, I. B., Dubuc-Lissoir, J., Fisher, B., Grimshaw, R., Oza, A. M., Plante, M., Stuart, G. C. E., and Vermorken, J. B., Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study., J Clin Oncol, vol. 18, no. 24, pp. 4038-44, 2000.
P. Hoskins, Vergote, I. B., Stuart, G. C. E., Cervantes, A., Tu, D., Carey, M. S., Provencher, D. M., Katsaros, D., P, G., and Eisenhauer, E., A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (OV.16). A GCIG Study., Proc.Am.Soc.Clin.Oncol. , vol. 26, no. 15S Part I, 2008.
T. Högberg, Signorelli, M., de Oliveira, C. F., Fossati, R., Lissoni, A., Sorbe, B., Andersson, H., Grenman, S., Lundgren, C., Rosenberg, P., Boman, K., Tholander, B., Scambia, G., Reed, N. Simon, Cormio, G., Tognon, G., Clarke, J., Sawicki, T., Zola, P., and Kristensen, G. B., Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies, Eur J Cancer, vol. 46, pp. 2422-31, 2010.
H. Hirte, Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B., Tu, D., Sadura, A., Brundage, M., and Seymour, L., A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a NCIC Group Study., Gynecol Oncol, vol. 102, no. 2, pp. 300-8, 2006.
H. Hirte, Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B., Tu, D., Sadura, A., Brundage, M., and Seymour, L., A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials G, Gynecol Oncol, vol. 102, pp. 300-8, 2006.
T. J. Herzog, Powell, M. A., Rader, J. S., Gibb, R. K., Lippmann, L., Coleman, R. L., and Mutch, D. G., Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer., Gynecol Oncol, vol. 111, no. 3, pp. 467-73, 2008.
T. J. Herzog, Vermorken, J. B., Pujade-Lauraine, E., Provencher, D. M., Jagiello-Gruszfeld, A., Kong, B., Boman, K., Park, Y. Choi, Parekh, T., Lebedinsky, C., Gómez, J., and Monk, B. J., Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study., Gynecol Oncol, vol. 122, no. 2, pp. 350-5, 2011.
M. L. Hensley, Barrette, B. A., Baumann, K. H., Gaffney, D. K., Hamilton, A. L., Kim, J. - W., Maenpaa, J. U., Pautier, P., Siddiqui, N. Ahmad, Westermann, A. M., and Ray-Coquard, I., Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S61-6, 2014.

Pages